New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023.

Autor:	Tamargo J; Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigación Sanitaria Gregorio Marañón, 28040 Madrid, Spain., Agewall S; Institute of Clinical Science, Oslo University, 0318 Oslo, Norway.; Institute of Clinical Sciences, Karolinska Institute, Danderyd Hospital, 171 77 Stockholm, Sweden., Borghi C; Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola, 40138 Bologna, Italy., Ceconi C; Motusmed Clinic, 25122 Brescia, Italy., Cerbai E; Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy., Dan GA; Carol Davila. University of Medicine, Colentina University Hospital, 0221 Bucharest, Romania., Ferdinandy P; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, H-1089, Hungary.; Pharmahungary Group, Budapest, H-1031, Hungary., Grove EL; Department of Cardiology, Aarhus University Hospital, 8200 Aarhus N, Denmark.; Department of Clinical Medicine, Faculty of Health, Aarhus University, 8200 Aarhus N, Denmark., Rocca B; Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.; Section of Pharmacology, Department of Safety and Bioethics, Catholic University School of Medicine, 00168 Roma, Italy., Magavern E; William Harvey Research Institute, Centre of Clinical Pharmacology and Precision Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK., Sulzgruber P; Department of Medicine, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria., Semb AG; Preventive Cario-Rheuma clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital, 0370 Oslo, Norway., Sossalla S; Cardiology and Angiology, Justus-Liebig-University, D-35392 Giessen, Germany.; Department of Cardiology, Kerckhoff-Clinic/DZHK, D-61234 Bad Nauheim, Germany., Niessner A; Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria., Kaski JC; Molecular and Clinical Sciences Research Institute, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK., Dobrev D; Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen, DE-45122 Essen, Germany.; Department of Medicine, Montreal Heart Institute and Université de Montréal, H1Y 3N1 Montréal, Canada.; Department of Integrative Physiology, Baylor College of Medicine, 77030 Houston, TX, USA.
Jazyk:	angličtina
Zdroj:	European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 May 04; Vol. 10 (3), pp. 219-244.
DOI:	10.1093/ehjcvp/pvae013
Abstrakt:	Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs. (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu